Actelion, Asahi Kasei Pharma cardiovascular news

A California arbitration panel decided that Actelion's CoTherix Inc. subsidiary must pay Asahi $91 million, plus interest, to settle a dispute regarding Actelion's termination of a June 2006 deal for fasudil. Asahi filed the dispute in 2007 after Actelion terminated the deal that granted CoTherix North American and European rights to the rho kinase inhibitor. The original deal was between Asahi and CoTherix, which was acquired by Actelion in December 2006. Fasudil was in development to treat pulmonary arterial hypertension (PAH) and angina. Actelion said it is reviewing the panel's decision (see BioCentury, Dec. 4, 2006 & April 23, 2007). ...